Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cantargia

1.31 SEK+2.27 %19/11 16:02
1,285 following

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+2.27 %
+0.15 %
-23.28 %
-61.42 %
-68.75 %
-61.81 %
-65.34 %
-91.15 %
-81.49 %

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Read more
Market cap
368.78M SEK
Turnover
389.99K SEK
Revenue
316.7M
EBIT %
48.66 %
P/E
2.22
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/11
2026

Interim report Q3'26

24/2
2027

Annual report '26

19/5
2027

Interim report Q1'27

Press release2026-11-09 07:30

Cantargia tillkännager IL-17 som andra måltavla för den bispecifika CAN14-antikroppen

Cantargia
Press release2026-11-09 07:30

Cantargia Announces IL-17 as Second Target for Bispecific CAN14 Antibody

Cantargia
Press release2026-11-05 08:00

Cantargia bjuder in till presentation av delårsrapport för Q3 2026

Cantargia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-05 08:00

Cantargia to host Q3 2026 Interim Results Conference Call

Cantargia
Press release2026-11-04 17:56

Redeye: Cantargia: Early Haematology Signal Ahead of ASH Oral

Cantargia
Regulatory press release2026-11-04 15:00

Cantargia presenterar lovande tidiga resultat med nadunolimab vid MDS och AML inför ASH 2026

Cantargia
Regulatory press release2026-11-04 15:00

Cantargia Presents Promising Early Results with Nadunolimab in MDS and AML Ahead of ASH 2026

Cantargia
Cantargia, Audiocast, Q3'26
Webcast2026-11-25 15:00

Cantargia, Audiocast, Q3'26

Cantargia
Regulatory press release2026-10-29 07:30

Cantargia presenterar valberedning inför årsstämman 2027

Cantargia
Regulatory press release2026-10-29 07:30

Cantargia presents Nomination Committee ahead of 2027 AGM

Cantargia
Press release2026-10-27 09:00

Cantargia presenterar på Stifel 2026 Healthcare Conference

Cantargia
Press release2026-10-27 09:00

Cantargia to Present at the Stifel 2026 Healthcare Conference

Cantargia
Regulatory press release2026-10-26 10:49

Finansinspektionen: Flaggningsmeddelande i CANTARGIA AB

Cantargia
Regulatory press release2026-10-26 10:36

Finansinspektionen: Flaggningsmeddelande i CANTARGIA AB

Cantargia
Regulatory press release2026-10-26 09:30

Cantargia utser Monic Stuart till Chief Medical Officer

Cantargia
Regulatory press release2026-10-26 09:30

Cantargia appoints Dr. Monic Stuart as Chief Medical Officer

Cantargia
Press release2026-09-30 07:00

Cantargia presenterar prekliniska data vid AACR som stödjer nadunolimab i kombination med RAS-hämning vid PDAC

Cantargia
Press release2026-09-30 07:00

Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC

Cantargia
Press release2026-09-10 09:00

BioStock: Cantargia presenterar på Investing in Life Science 22 september

Cantargia
Press release2026-09-10 09:00

BioStock: Cantargia to Present at Investing in Life Science on September 22

Cantargia